Patients
We’re developing regenerative therapies designed to enhance the body’s natural ability to repair muscle. Every decision we make is guided by scientific rigor, patient safety, and a commitment to the people and families living with degenerative muscle diseases.
At Satellos, our mission is to develop new medicines that improve muscle regeneration for people living with degenerative muscle diseases. We’re advancing regenerative therapies designed to help the body repair muscle naturally, with programs focused on conditions where this process is impaired, including Duchenne muscular dystrophy (“DMD” or “Duchenne”) and facioscapulohumeral muscular dystrophy (FSHD). Every step of our work is guided by urgency, scientific rigor, and an unwavering commitment to the patients and families we hope to serve.
Forazapadin (SAT-3247) is currently being evaluated across two Phase 2 clinical trials in Duchenne.
Forazapadin is an investigational oral therapy designed to enhance the body’s natural ability to repair muscle. It targets a biological pathway involved in muscle stem cell function, helping enhance the regenerative process that allows damaged muscle to be repaired.
Muscle regeneration is impaired in several degenerative muscle diseases, including DMD and FSHD. By restoring this process, we hope to help the body repair and regenerate muscle in response to damage as nature intended.
Want to learn how muscle regeneration works?
SAT-3247-CL-201: Phase 2 BASECAMP Study
Summary
This is a global Phase 2a trial of forazapadin (SAT-3247) in ambulatory DMD patients aged ≥ 7 and < 10 years. The trial will study two doses of forazapadin in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy.
Participants
51 ambulatory DMD participants aged ≥ 7 and < 10 years of age
Locations
U.S., UK, EU (Belgium, Spain, Poland), Serbia, Canada, and Australia.
For more information, visit: clinicaltrials.gov/study/NCT07287189
SAT-3247-LT-001: Phase 2 TRAILHEAD Study
Summary
This is an open-label long-term safety and efficacy study of orally administered forazapadin (SAT-3247) in patients with DMD that previously participated in SAT-3247-CL-101. The study will assess the long-term safety, tolerability and potential efficacy of a 60 mg of orally administered forazapadin.
Participants
Individuals who completed the initial Phase 1b trial
Location
Melbourne, Australia
For more information on this study, visit: clinicaltrials.gov/study/NCT06867107
Charlie’s Story
A family’s long-awaited joy turned to heartbreak when their young son was diagnosed with Duchenne muscular dystrophy. Through determination, hope, and the promise of science, they’ve found a path forward — but questions remain about what the future will hold. Read their story of love, resilience, and daring to dream of a different outcome.
We recognize the urgent need for new treatment options for people living with degenerative muscle diseases, including Duchenne and FSHD. While we are working to advance the development of forazapadin as quickly as possible, it is currently available only through clinical trials.
Where We Are Now
- Forazapadin is currently being evaluated in clinical trials to better understand its safety and potential benefits. Additional clinical data are needed before broader access outside of clinical trials can be considered.
What This Means
- Patient safety is our highest priority. At this stage, we believe additional clinical evidence is needed before forazapadin can be made available outside of controlled clinical trials.
- We understand this may be disappointing for individuals and families seeking new treatment options, and we are committed to advancing development as quickly as possible while maintaining rigorous safety standards.
- We will continue to evaluate opportunities for expanded access as our clinical programs progress and as permitted by applicable laws and regulations.
Satellos is committed to reaching people of all ages with forazapadin as quickly as possible, guided by the data and with safety always in mind.
Satellos regularly reviews its policies to ensure they align with applicable laws and regulations. We may update this policy at any time as needed.